Demonstration Kit

This kit demonstrates the compact storage size and portability of Novo Nordisk products like Novoeight^®, and helps you show patients how quick it is to reconstitute a dose. Patients may practice mixing a placebo dose to become familiar with the process before leaving your office. Please see full Prescribing Information for complete Instructions for Use for Novoeight^®.

To order a Demonstration Kit, please contact a

Novo Nordisk representative.

Related Information

We’ve created additional, easy-to-share resources to address your questions about Novoeight^®.

Choose from these materials:

Novoeight^® Small Kit

Also available from Novo Nordisk:

Visit website | Prescribing Information

Selected Important Safety Information

Contraindications

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight^® or its components, including hamster proteins

Warnings and Precautions

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight^® and administer appropriate treatment

Indications and Usage

Novoeight^® (antihemophilic factor, recombinant) is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.

Novoeight^® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight^® or its components, including hamster proteins

Warnings and Precautions

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight^® and administer appropriate treatment
Development of activity-neutralizing antibodies (inhibitors) may occur. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all factor VIII products. Inhibitors have been reported following administration of Novoeight in PUPs. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform testing for factor VIII inhibitors

Adverse Reactions

The most frequently reported adverse reactions (≥1%) were inhibitors in Previously Untreated Patients (PUPs), injection site reactions, and pyrexia.

Novoeight®

[Antihemophilic Factor (Recombinant)]